SecBot SecBot
8-K ·Filed Nov 12, 2026

TRAW

Traws Pharma, Inc.
NEUTRAL
Impact 4/10
Horizonmonths Processed4d 16h ago SEC0001104659-26-125797
8-K context-dependent: Items 7.01
Actionable Insight • Neutral

Monitor for FDA feedback on ratutrelvir's registration path and potential Fast Track designation, as well as the outcome of TXM's regulatory resubmission in Q4 2026. The company's ability to raise additional capital remains a key risk given its $4M market cap and clinical-stage status.

DirectionNeutral
Confidencemedium
Horizonmonths

Drugs in focus

TRAW drug pipeline →

ratutrelvir

● Neutral Named in this 8-K
Impact
Phase
Phase 2
Time to market
Unknown — Phase 2a is complete but no Phase 3 trial has been announced. If Phase 3 starts in 2026-2027, potential FDA submission would be at least 2-3 years away.
Next catalyst
None dated

What to watchRatutrelvir's Phase 2 data (completed Feb 2026) showed a differentiated safety profile vs Paxlovid, but the company has not yet outlined a path to Phase 3 or given a timeline. Meanwhile, Traws Pharma's other drug (tivoxavir marboxil) has an FDA clinical hold and both covering analysts downgraded TRAW to Neutral in June 2026. Watch for a Phase 3 announcement or FDA meeting readout as the next potential catalyst; without one, ratutrelvir is a long-odds development-stage asset at a cash-strapped micro-cap.

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1
Entry
$0.2848
T+0 close · Nov 12, 2026 · via day close
Latest settled
−11.87%
T+1 · $0.2510
Vs SPY
−11.50%
α at T+1
Next horizon
T+5
in 2d
  1. T+0 · Nov 12 $0.2848entry
  2. T+1 · 4d ago −11.87%α −11.50% · $0.2510
  3. T+2 · todayOpen
  4. T+5 · in 2d Pending
  5. T+20 · in 24d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Traws Pharma announced final Phase 2a results for ratutrelvir in COVID-19, showing comparable symptom resolution to PAXLOVID with fewer adverse events and no viral rebound, and completed a bridging study for tivoxavir marboxil (TXM) tablet formulation. The company plans to discuss a registration path with the FDA focused on PAXLOVID-ineligible patients and expects to resubmit TXM's toxicology package in Q4 2026.

Key Facts

  • Phase 2a study of ratutrelvir enrolled 92 patients with mild-to-moderate COVID-19
  • In PAXLOVID-eligible patients, median time to sustained symptom resolution was 13.5 days for ratutrelvir vs 14.5 days for PAXLOVID
  • No virologic rebound observed through Day 28 with ratutrelvir
  • Treatment-related adverse events: 1 of 32 ratutrelvir patients vs 4 of 30 PAXLOVID patients
  • In PAXLOVID-ineligible subjects (30 patients), symptoms resolved in 14.0 days with no treatment-related adverse events
  • TXM tablet bridging study showed comparable exposure to powder-in-capsule and was well tolerated
  • TXM toxicology retest completed; no mutagenic effect at doses up to 500 mg/kg; regulatory resubmission planned for Q4 2026
  • Company intends to discuss with FDA a registration strategy focused on PAXLOVID-ineligible patients

Financial Impact

No financial figures provided; company is clinical-stage with $4M market cap

Risk Factors

  • Ratutrelvir and TXM are investigational and have not been approved by any regulatory authority
  • TXM is under FDA clinical hold as noted in forward-looking statements
  • Company has $4M market cap and may need to raise additional capital to fund development
  • Phase 2a data is from a small 92-patient study; larger pivotal trials are needed
  • Forward-looking statements about FDA discussions and registration path may not materialize

Market Snapshot

Exchange
CBOE
Analyst Consensus
0% bullish (7 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001104659-26-125797
Document: tm2629616d1_8k.htm0001104659-26-125797
Document: 0001104659-26-125797-index-headers.html0001104659-26-125797
Document: 0001104659-26-125797-index.html0001104659-26-125797
Document: 0001104659-26-125797.txt0001104659-26-125797

Track record

29 reports on TRAW

Performance horizon

10 of 11 bullish or bearish reports moved the stock their way by T+20. Best: +72.58% at T+60 after the May 8, 2026 report. 14 of 15 went positive at some point.

Filters
  1. Nov 16, 2026today Press Release Neutral 4/10 Entry price pending
  2. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry price pending
  3. Nov 13, 20263d ago EFFECT Bearish 7/10 Entry $0.2510 Now $0.2600 −3.59% settles Dec 14
  4. Nov 12, 20264d ago 8-K Neutral 4/10 Viewing Entry $0.2848 Now $0.2600 −8.71% settles Dec 11
  5. Oct 26, 202621d ago S-1 Bearish 6/10 Entry $0.3660 Now $0.2600 +28.96% settles Nov 24
  6. Oct 23, 202624d ago 8-K Bearish 7/10 Entry $0.3411 Now $0.2600 +23.78% settles Nov 23
  7. Oct 20, 202627d ago DEFA14A Neutral 3/10 Entry $0.3760 Now $0.2600 −30.85% settles Nov 18
  8. Oct 20, 202627d ago DEF 14A Bearish 6/10 Entry $0.3760 Now $0.2600 +30.85% settles Nov 18
  9. Aug 14, 202613w ago Press Release Bearish 5/10 Entry $0.5400 to $0.5200 Now $0.2600 +51.85% ▲ +3.70% +2.18% vs SPY
  10. Jul 10, 202618w ago 8-K Bearish 6/10 Entry $0.6849 to $0.5400 Now $0.2600 +62.04% ▲ +21.16% +24.34% vs SPY
Showing 10 of 29

US Market Status

Market Closed · Opens Wed (10h 19m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 12, 2026